Evolent Health, Inc. (EVH)
NYSE: EVH · IEX Real-Time Price · USD
19.69
-0.44 (-2.19%)
At close: Jul 19, 2024, 4:00 PM
11.10
-8.59 (-43.62%)
After-hours: Jul 20, 2024, 1:23 PM EDT
Evolent Health Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Evolent Health stock have an average target of 41.75, with a low estimate of 34 and a high estimate of 52. The average target predicts an increase of 112.04% from the current stock price of 19.69.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 10, 2024.
Analyst Ratings
The average analyst rating for Evolent Health stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 3 | 5 | 5 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $44 → $41 | Strong Buy | Maintains | $44 → $41 | +108.23% | May 10, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $38 → $34 | Buy | Maintains | $38 → $34 | +72.68% | May 10, 2024 |
| Citigroup | Citigroup | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +103.15% | Apr 22, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $45 → $44 | Strong Buy | Maintains | $45 → $44 | +123.46% | Mar 28, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $53 → $52 | Buy | Maintains | $53 → $52 | +164.09% | Mar 15, 2024 |
Financial Forecast
Revenue This Year
2.60B
from 1.96B
Increased by 32.49%
Revenue Next Year
2.99B
from 2.60B
Increased by 14.99%
EPS This Year
1.35
from -1.28
EPS Next Year
1.71
from 1.35
Increased by 27.41%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.7B | 3.3B | 3.9B | 4.6B | 5.5B |
| Avg | 2.6B | 3.0B | 3.4B | 3.9B | 4.5B |
| Low | 2.5B | 2.8B | 3.0B | 3.3B | 3.5B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 39.0% | 28.3% | 28.9% | 34.8% | 41.6% |
| Avg | 32.5% | 15.0% | 14.4% | 13.8% | 14.5% |
| Low | 27.2% | 6.5% | 0.6% | -5.0% | -10.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.71 | 2.49 | 2.91 | 2.79 | 3.61 |
| Avg | 1.35 | 1.71 | 1.98 | 2.69 | 3.47 |
| Low | 0.75 | 1.04 | 1.25 | 2.61 | 3.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 84.9% | 69.5% | 41.4% | 34.4% |
| Avg | - | 27.4% | 15.3% | 36.0% | 29.3% |
| Low | - | -22.8% | -26.8% | 31.9% | 25.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.